Sang-A Frontec Co.Ltd (089980) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Sang-A Frontec Co.Ltd stock KRW 8,677, price KRW 12,290, that is 29.4% below the price, quality 44 out of 100. Rating: overvalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range 11,500 KRW – 73,339 KRW · fair‑value band 6,650 KRW – 12,350 KRW · the 12,290 KRW price screens above the 8,677 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Sang-A Frontec Co.Ltd in your weekly email
Every Wednesday you see whether Sang-A Frontec Co.Ltd is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Sang-A Frontec Co.,Ltd. engages in the research and development, production, and sale of materials/parts based on engineering plastics in South Korea and internationally.
Show moreShow less
The company offers fuel cells; membranes, including vent filters and ePTFE for textiles, as well as membranes for medical use; semiconductor products, such as jar boxes, solar cassettes, FOUP products, wafer carriers, storage boxes, PFA/FEP tubes, and mold release films; medium and large, cylindrical, and small type batteries; and display products comprising cell cassettes, ACF bonding sheets, support bars, and FPD cassettes.
It also provides automotive products consisting of air vents, and PTFE tubes and rings; OA products that include wireless charging kits, laser printer/MFP/copy machines, metal sleeves, fuser films, fuser and transfer belts, and guide claws; SG and LX sheet, and backup board PCBs; and medical devices, such as safety filter syringes, epidural needle kits, Green Medi green VACs, and filter needle syringes.
The company was founded in 1974 and is headquartered in Incheon, South Korea.
Stock analysis
Sang-A Frontec Co.Ltd (089980) currently trades at 12,290 KRW, while our model-based Fair Value estimate is 8,677 KRW, 29% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 12,094 KRW per share, and 2 of the 14 models we run sit above the 12,290 KRW price.
Bear case: the Dividend Discount group reads lowest at 1,686 KRW, and 12 of the 14 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 6,650 KRW (bear) to 12,350 KRW (bull), the price of 12,290 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 44/100 (below-average quality), in the Technology sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Sang-A Frontec Co.Ltd reported revenue of 196B KRW in FY2025 versus 178B KRW in FY2021, a compound +2.4%/yr. Reported net income was 6.8B KRW in FY2025, compounding −7.7%/yr from FY2021.
Key figures
Market cap 191B KRW (≈ $141M) Micro · P/E ratio 21.4 · P/S ratio 0.89 · EPS (TTM) 629.95 KRW · Dividend yield 1.6% · Net margin 4.6% · Return on equity 4.9% · Return on assets (EBIT) 2.7% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 31 out of 100 (low confidence).
What moves the price
The share trades about 58% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Technology peers we cover trades at −7% fair-value upside, at −29%, 089980 screens richer than that median.
Fair Value models
Bear6,650 KRWFair Value 8,677 KRWBull12,350 KRW
Price 12,290 KRW · Downside -29.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (368.70 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.37/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+14.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.0%
Start year 2020 (pandemic). Over 10 years: +3.1% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−4.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−6.2%
Dividend (yield on the price)1.6%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−6.2% vs 0.4%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.5% → 3%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Electronic Components · 653 stocks
Beats the industry median on 9/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score44 · Below median
Fair Value upside−29.4% · Above median
Profitability
Return on equity (12 months)4.9% · Below median
Return on assets1.8% · Below median
Net margin (12 months)4.6% · Below median
Operating margin (12 months)6.4% · Above median
Growth and dividend
Revenue growth (quarter YoY)24.8% · Above median
Dividend yield (12 months)1.6% · Above median
Balance sheet
Debt / equity0.05× · Below median
Valuation Multiplesvs Electronic Components median · lower = cheaper
P/E (12 months)21.4× · Cheaper than median
P/B0.94× · Cheapest 25%
P/S (12 months)0.89× · Cheapest 25%
EV/EBITDA6.9× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 70
PAST (return on equity)19· sector 28
HEALTH (low debt)98· sector 95
DIVIDEND (yield)33· sector 27
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Sang-A Frontec Co.Ltd (089980) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 8,677 KRW versus a price of 12,290 KRW, about 29% lower (overvalued).
What is the fair value of 089980?
Our model-based fair value for Sang-A Frontec Co.Ltd is 8,677 KRW (as of Nov 8, 2026), built from audited fundamentals. The current price: 12,290 KRW.
What is the quality score of 089980?
Sang-A Frontec Co.Ltd has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sang-A Frontec Co.Ltd (089980)?
Our model-based price target is the fair value of 8,677 KRW (as of Nov 8, 2026) from 14 valuation models. Cautious scenario 6,650 KRW, optimistic scenario 12,350 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Sang-A Frontec Co.Ltd stock forecast for 2026?
Our models put fair value at 8,677 KRW, about 29% lower versus a price of 12,290 KRW (overvalued). Cautious scenario 6,650 KRW, optimistic scenario 12,350 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Sang-A Frontec Co.Ltd (089980)?
Sang-A Frontec Co.Ltd reported trailing-twelve-month revenue of about 215B KRW (latest available figure, as of Nov 8, 2026).
Does Sang-A Frontec Co.Ltd pay a dividend?
Sang-A Frontec Co.Ltd currently shows a dividend yield of 1.63% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Sang-A Frontec Co.Ltd (089980) and when is the ex-dividend date?
Sang-A Frontec Co.Ltd pays a dividend of 200.00 KRW per share a year, a dividend yield of 1.6%. The last ex-dividend date was Dec 29, 2025. A dividend has been paid every year since at least 2011. The payout ratio is 33.6% of earnings (on adjusted earnings, reported 31.7%). Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of Sang-A Frontec Co.Ltd (089980)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sang-A Frontec Co.Ltd it is 8,677 KRW per share (as of Nov 8, 2026), against a price of 12,290 KRW. It is the blended result of 14 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Sang-A Frontec Co.Ltd stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 089980 trades above its calculated fair value: price 12,290 KRW, fair value 8,677 KRW, a gap of about −29% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 089980?
No. The price is what the market pays today (12,290 KRW); the fair value is what the company's own numbers justify (8,677 KRW). For Sang-A Frontec Co.Ltd the two are 3,613 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Sang-A Frontec Co.Ltd worth?
The market values Sang-A Frontec Co.Ltd at about 191B KRW (market capitalisation, as of Nov 8, 2026). Per share that is 12,290 KRW; our models calculate a fair value of 8,677 KRW per share.
What do the bullish and bearish scenarios say about 089980?
Our models span a range for Sang-A Frontec Co.Ltd: cautious scenario 6,650 KRW, base 8,677 KRW, optimistic 12,350 KRW per share (as of Nov 8, 2026, price 12,290 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 089980?
Sang-A Frontec Co.Ltd trades at a price-to-earnings ratio of 21.4 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 8,677 KRW is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 30.0 (reported for FY2025: 28.4). Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings, FY2025 ex one-offs: 33.4. Other multiples: P/B 0.9, P/S 0.9, EV/EBITDA 6.9.
How solid is the balance sheet of Sang-A Frontec Co.Ltd (089980)?
Balance-sheet figures for Sang-A Frontec Co.Ltd (as of Nov 8, 2026): return on equity 4.9%, debt of 0.05 per unit of equity. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is 089980 from its 52-week high?
Sang-A Frontec Co.Ltd trades at 12,290 KRW, about 58% below its 52-week high of 29,250 KRW and 7% above the low of 11,500 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 8,677 KRW is for.
Which stocks are comparable to Sang-A Frontec Co.Ltd?
From the same area (Technology) we also value Amphenol Corporation, Hon Hai Precision Industry Co, Corning Incorporated, Delta Electronics, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sang-A Frontec Co.Ltd stock attractive at the current price?
The data as of Nov 8, 2026: price 12,290 KRW, calculated fair value 8,677 KRW (−29%), Quality Score 44/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 089980 calculated?
We run Sang-A Frontec Co.Ltd through 14 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 8,677 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Sang-A Frontec Co.Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sang-A Frontec Co.Ltd (089980)?
The closing price on Nov 6, 2026 was 12,290 KRW. Our model-based fair value is 8,677 KRW, about 29% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sang-A Frontec Co.Ltd right now?
Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range (6,650 KRW to 12,350 KRW) leaves room in how you read the outcome.
Key figures of Sang-A Frontec Co.Ltd
How large is the market capitalisation of Sang-A Frontec Co.Ltd (089980)?
The market capitalisation of Sang-A Frontec Co.Ltd is 191B KRW (≈ $141M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sang-A Frontec Co.Ltd (089980)?
The price-to-sales ratio of Sang-A Frontec Co.Ltd is 0.89 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sang-A Frontec Co.Ltd (089980)?
Earnings per share at Sang-A Frontec Co.Ltd are 629.95 KRW (price ÷ EPS = P/E 21.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Sang-A Frontec Co.Ltd (089980)?
The dividend yield of Sang-A Frontec Co.Ltd is 1.6% (payout 33.6%, on adjusted earnings, reported 31.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Sang-A Frontec Co.Ltd (089980)?
The net margin of Sang-A Frontec Co.Ltd is 4.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sang-A Frontec Co.Ltd (089980)?
The return on equity (ROE) of Sang-A Frontec Co.Ltd is 4.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sang-A Frontec Co.Ltd (089980)?
On an EBIT basis the return on assets of Sang-A Frontec Co.Ltd is 2.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sang-A Frontec Co.Ltd (089980)?
The operating margin of Sang-A Frontec Co.Ltd is 6.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sang-A Frontec Co.Ltd (089980)?
Revenue at Sang-A Frontec Co.Ltd is growing +24.8% versus a year earlier (3y avg +2.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sang-A Frontec Co.Ltd (089980)?
Earnings per share at Sang-A Frontec Co.Ltd are growing +115% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Sang-A Frontec Co.Ltd (089980) generate?
The free cash flow of Sang-A Frontec Co.Ltd is −21.6B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Sang-A Frontec Co.Ltd (089980) carry?
The net debt of Sang-A Frontec Co.Ltd is 119B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Sang-A Frontec Co.Ltd in the live analysis
One click puts Sang-A Frontec Co.Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 8, 2026